Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.NOVATO, Calif., Nov. 20, 2024 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel therapies for rare and ultrarare diseases, today reported the grant of 20,820 restricted stock units of the company's common stock to 13 newly hired non-executive officers of the company. The awards were approved by the compensation committee of the company's board of directors and granted under the Ultragenyx Employment Inducement Plan, with a grant date of November 16, 2024, as an inducement material to the new employees entering into employment with Ultragenyx in accordance with Nasdaq Listing Rule 5635(c)(4).
加利福尼亞諾瓦託，2024年11月20日 (環球新聞社) -- ultragenyx pharmaceutical 公司（NASDAQ: RARE）是一家專注於罕見和超罕見疾病新療法開發和商業化的生物製藥公司，今天報告稱，公司董事會薪酬委員會批准向公司13名新任非執行官授予20,820股限制性股票單位，這些獎勵授予在ultragenyx就業誘導計劃下批准，並於2024年11月16日授予，作爲新員工按照Nasdaq上市規則5635(c)(4)與ultragenyx簽訂就業協議的誘因重要素材。
The restricted stock units vest over four years, with 25% of the underlying shares vesting on each anniversary of the grant date, subject to the employee being continuously employed by the company as of such vesting dates.
限制性股票實行四年分期歸屬，股票的25%將在授予日期的每個週年之日授予，但前提是該員工在歸屬日期繼續爲公司工作。
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultrarare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
關於Ultragenyx Pharmaceutical Inc.
Ultragenyx是一家生物製藥公司，致力於爲罕見的和極其罕見的遺傳病提供新型治療產品。該公司已構建了一個多樣化的批准治療方案和產品候選組合，旨在解決存在高需求和明確生物學治療的疾病，而通常沒有治療相關潛在疾病的批准治療方案。
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx's strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
該公司由一支有豐富罕見病治療藥物開發和商業化經驗的管理團隊領導。Ultragenyx 的策略基於及時高效的藥品研發，旨在以最大的緊迫性向患者提供安全有效的治療。
For more information on Ultragenyx, please visit the company's website at: .
有關Ultragenyx的更多信息，請訪問該公司的網站。
Contact Ultragenyx
Investors & Media
Joshua Higa
(415) 475-6370
聯繫超凡妥
投資者和媒體
Joshua Higa
（415）475-6370
